Hematology Oncology Market Destine to Reach USD 14.83 Billion by 2029, Size, Share, Industry Growth Rate, Demand & Revenue Outlook

The haematology oncology market is benefited by advantageous reimbursement policies, pharmaceutical industry cooperation, and the rise in healthcare spending. Increasing investment for healthcare infrastructure. This boosts the market.

| Source: Data Bridge Market Research Data Bridge Market Research

CHICAGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- A Qualitative Research Study accomplished by Data Bridge Market research's database of 350 pages, titled as “Global Hematology Oncology Market” with 100+ market data Tables, Pie Charts, Graphs & Figures spread through Pages and easy-to-understand detailed analysis. The data and information of this Hematology Oncology report help businesses map the advertising, promotion, marketing, and sales strategy more profitably and also assist in taking sound and efficient decisions. Qualitative and transparent research studies are performed devotedly to offer you an excellent market research report for your niche. Hematology Oncology market research report conducts a precise analysis of the current scenario of the market, which covers several market dynamics. In the Hematology Oncology market report, market drivers and market restraints are studied carefully along with the analysis of the market structure. Not to mention, several charts and graphs have been used effectively to represent the facts and figures properly.

Data Bridge Market Research analyses that the Hematology Oncology Market which was USD 8.13 billion in 2021, would rocket up to USD 14.83 billion by 2029, and is expected to undergo a CAGR of 7.80% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get Access to Sample Report (Including Graphs, Charts & Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hematology-oncology-market

Market Overview:-

Hematology is the study of blood and bone marrow illnesses and includes their diagnosis, prevention, and therapy. The field of medicine known as oncology is primarily concerned with treating and diagnosing cancer. Hematology is commonly used in treatments for conditions including diabetes, cancer, cardiovascular disease, and blood screening, among others. The three main fields of oncology are medicine, surgery, and radiation.

The market for hematology oncology is expected to grow during the forecast period of 2022-2029. The rising incidence of myeloma and lymphoma worldwide is one of the main drivers of the hematology-oncology market's revenue growth. Because of the proliferation of sequencing techniques like next-generation sequencing (NGS) as a result of rising development costs and the sequencing of the human genome project (HGP) in the field of genomics, market expansion prospects are also improving as a result of the increase in the accessibility of better molecular techniques for the diagnosis of hemato-oncology.

Opportunities

  • The rise in cases of blood disorders

The hematology oncology market's growth is fuelled by the advent of cutting-edge molecular approaches to address issues with blood cancer prognosis, course of therapy, and diagnostics, as well as the rise in cases of blood disorders. This will provide beneficial opportunities for the hematology oncology market growth.

Moreover, an increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the growth of hematology oncology market during the forecast period.

Some of The Key Players Covered in the Hematology Oncology Market:

  • Illumina, Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Agilent Technologies Inc. (U.S.)
  • Myriad Genetics Inc. (U.S.)
  • Beijing Genomics Institute (BGI)
  • Perkin Elmer Inc. (U.S.)
  • Foundation Medicine Inc. (U.S.)
  • PacBio (U.S.)
  • Oxford Nanopore Technologies plc. (U.K.)
  • Paradigm Diagnostics Inc. (U.S.)
  • Caris Life Sciences (Japan)
  • Partek, Incorporated (U.S.)
  • Eurofins Scientific (Luxembourg)
  • Qiagen (Germany)

Access 350 Pages Full PDF Report @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-hematology-oncology-market

Recent Development

  • In June 2022, Thermo Fisher Scientific Inc. expanded its extensive line of automated connective tissue disease tests by releasing the new EliA RNA Pol III and EliA Rib-P blood tests to assist in the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematosus (SLE).
  • In May 2020, The DxH 690T haematology analyzer was introduced by Beckman Coulter, a division of Danaher Corporation, in the United States. It enables mid-volume laboratories to optimise uptime and streamline workflow.

The Primary Objectives of This Global Market Research Report Are as Follows:

  • To understand this market competition by analysing the top vendors, with their market profile, revenue, profits, import-export details, and market share
  • To analyze the product type, applications and regional presence of this Industry
  • To state the pricing structure, import-export details, supply chain analysis, Porter’s Five Forces analysis to facilitate the key decision-making process
  • To provide the complete structure and fundamental overview of this Industry
  • To offer insights into vital this market aspects like growth trajectory, CAGR value, market share, and revenue analysis
  • To evaluate the growth opportunities, threats, market drivers, and risks involved
  • To boost the future growth, investment analysis and upcoming growth opportunities with the analysis of emerging market segments and sub-segments
  • To present the historic, present, and forecast market analysis with product developments, joint ventures, and strategic alliances
  • To study the recent developments, emerging sectors, new product launch events, and mergers & acquisitions in this market
  • To understand the data sources, implied research methodology, and vital conclusions

Key Market Segmentation:

By Hematology Product

  • Hematology Analyzers
  • Hematology Reagents
  • Flow Cytometers
  • Hematology Cell Counters
  • Slide Strainers
  • Coagulation Analyzers
  • Hematology Testing
  • Centrifuges
  • Hemoglobin meters
  • Others

 By Oncology Drug Class Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy

By Oncology Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Others

 By Applications

  • Infectious Diseases
  • Cancer
  • Cardiovascular Disorders
  • Blood Screening
  • Diabetes
  • HIV
  • Auto–Immune Diseases

By End Users

  • Hospitals
  • Clinical Testing Institutes
  • Patient Self-Testing
  • Other End-Users 

To Gain More Insights about this Research, Visit @ https://www.databridgemarketresearch.com/reports/global-hematology-oncology-market

Global Hematology Oncology Market Dynamics

Drivers

  • The rise in the prevalence of lymphoma and myeloma

The main factors propelling the expansion of the haematology oncology market is the rise in the prevalence of lymphoma and myeloma around the world. The creation and sequencing of the Human Genome Project has become more expensive, leading to a proliferation of sequencing methods like NGS. The availability of more sophisticated molecular techniques for the diagnosis of hemato oncology has also increased. The advent of cutting-edge molecular approaches to address issues with blood cancer prognosis, course of therapy, and diagnostics, as well as the rise in cases of blood disorders, have a further impact on the market.

  • Rise in healthcare infrastructure

The haematology oncology market is benefited by advantageous reimbursement policies, pharmaceutical industry cooperation, and the rise in healthcare spending. Increasing investment for healthcare infrastructure. This boosts the market.

  • Rise in the geriatric population

The rising prevalence rates of lifestyle disorders like as rising healthcare spending, and the fast-growing diagnostic industry, are driving the worldwide hematology oncology market expansion. In addition, the growing elderly population, increased demand for laboratory automation, and more awareness of preventative healthcare are all driving the hematology oncology market forward.

Restraints/Challenges

  • High cost

On the other hand, the high cost associated with the cancer drugs will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hematology oncology market.

  • Hematology Oncology Market Regional Analysis/Insights

The hematology oncology market is analysed and market size insights and trends are provided by country, hematology product, oncology drug class type, oncology indication, applications and end users as referenced above.

The countries covered in the hematology oncology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hematology oncology market due to rise in incidence of leukemia, lymphoma, and multiple myeloma within the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing number of research activities conducted by various academic research institutes in the region.

TABLE OF CONTENTS

Part 01: Executive Summary

Part 02: Scope of the Report

Part 03: Research Methodology

Part 04: Market Landscape

Part 05: Pipeline Analysis

Part 06: Market Sizing

Part 07: Five Forces Analysis

Part 08: Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers and Challenges

Part 13: Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

View Detailed Table of Content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hematology-oncology-market

The Hematology Oncology market report provides answers to the following key questions:

  • What will be the Hematology Oncology market size and the growth rate in the coming year?
  • What are the main key factors driving the global Hematology Oncology market?
  • What are the key market trends impacting the growth of the global Hematology Oncology market?
  • Which are Trending factors influencing the market shares of the top regions across the globe?
  • Who are the key market players and what are their strategies in the global Hematology Oncology market?
  • What are the market opportunities and threats faced by the vendors in the global Hematology Oncology market?
  • What industrial trends, drivers and challenges are manipulating its growth?
  • What are the key outcomes of the five forces analysis of the global Hematology Oncology market?

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, West Europe or Southeast Asia

Explore More Reports:-

  • Interventional Oncology Devices Market, By Product Type (Embolization Devices, Ablation Devices, Support Devices, Next-Gen Devices), Cancer Type (Liver Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Bone Cancer, Kidney Cancer, Others), Procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, Transcatheter Arterial Embolization/Bland Embolization),  Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-interventional-oncology-devices-market
  • Immuno-Oncology (IO) Market, By Type (Immune Cell Therapy (CAR-T), Monoclonal Antibodies, Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Others), Targets (LAG-3, anti-CTLA-4, MAGE-A3, VEGF, HDAC, STING, TIM-3, TGF-Beta, OX40, Others), Indication (Malignant Tumors, Benign Tumors, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-immuno-oncology-market
  • Hemato Oncology Testing Market, By Product and Services (Services, Assay Kits), Cancer Type (Leukemia, Lymphoma, Other Cancers), Technology (PCR, IHS, NGS, Cytogenetics, Other), End Users (Clinical Laboratories, Hospitals, Academic and Research Institutes, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast https://www.databridgemarketresearch.com/reports/global-hemato-oncology-testing-market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com


Mot-clé

Hematology Oncology Market Hematology Oncology industry

Hyperliens